All In Biotech

Drug Trial Radar · NCT00605280

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 317 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

317

Actual

Start

Sep 2005

Primary completion

Nov 2009

Study completion Jul 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.

Conditions

  • Macular Edema Associated With Diabetes Mellitus

Interventions

  • Standard of CareDrug

    Clinicians decision to use optional laser therapy.

  • MacugenDrug

    Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 YearTime frame: Baseline, Year 1

Locations

73 sites in 18 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Oakland, California

  • Pfizer Investigational Site

    Santa Ana, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Hamden, Connecticut

  • Pfizer Investigational Site

    Fort Lauderdale, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Augusta, Georgia

  • Pfizer Investigational Site

    ‘Aiea, Hawaii

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Wichita, Kansas

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Lynbrook, New York

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Charlotte, North Carolina

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania

  • Pfizer Investigational Site

    West Columbia, South Carolina

  • Pfizer Investigational Site

    Abilene, Texas

  • Pfizer Investigational Site

    Fort Worth, Texas

  • Pfizer Investigational Site

    Houston, Texas

  • Pfizer Investigational Site

    McAllen, Texas

  • Pfizer Investigational Site

    San Antonio, Texas

  • Pfizer Investigational Site

    Temple, Texas

  • Pfizer Investigational Site

    Milwaukee, Wisconsin

  • Pfizer Investigational Site

    East Melbourne, Australia

  • Pfizer Investigational Site

    Westmead, New South Wales, Australia

  • Pfizer Investigational Site

    Innsbruck, Austria

  • Pfizer Investigational Site

    Vienna, Austria

  • Pfizer Investigational Site

    Porto Alegre, Brazil

  • Pfizer Investigational Site

    São Paulo, Brazil

  • Pfizer Investigational Site

    São Paulo, Brazil

  • Pfizer Investigational Site

    Gioania, Goiás, Brazil

  • Pfizer Investigational Site

    Vancouver, British Columbia, Canada

  • Pfizer Investigational Site

    Montreal, Quebec, Canada

  • Pfizer Investigational Site

    Bogotá, Colombia

  • Pfizer Investigational Site

    Brno, Czechia

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.